吸入疗法的创新和增长机会

本报告对吸入疗法进行了研究分析，重点介绍了可吸入生物製剂的关键处方，并研究了推动或抑制市场增长的因素。 它还检查了正在开发的单克隆抗体和疫苗的管道，并评估了研发趋势、伙伴关係和协作趋势、资金和投资分析、专利分析和可吸入生物製剂的前景。

内容

战略要务

• 为什么增长越来越难？
• 战略要务 8 (TM)
• 吸入疗法行业三大战略要务的影响
• 增长机会推动增长 Pipeline Engine(TM)
• 调查方法

增长机会分析

• 分析范围
• 需要吸入生物製剂
• 吸入给药：简介
• 细分：吸入製剂
• 吸入剂型和给药系统的优缺点
• 可吸入生物製剂和药物输送系统的新配方示例
• 有前途的吸入疗法：吸入单克隆抗体 (mAb) 和疫苗的优势
• 增长动力
• 抑制增长的因素

行业评估与分析

• 吸入疫苗和单克隆抗体的管道分析
• 临床开发中的疫苗和单克隆抗体
• 主要技术：AttenuBlock 平台技术（候选减毒活疫苗的密码子去优化）
• 关键技术：纳米乳剂平台（鼻内佐剂技术）

创新生态系统

• 研发趋势
• 协作和伙伴关係趋势
• 融资和投资分析
• 专利分析
• 未来路线图

增长机会领域

• 增长机会 1：使用纳米技术通过药物再利用製造雾化器解决方案
• 增长机会 2：与 CDMO 结盟以提供端到端服务
• 增长机会 3：用于安全吸入给药的基于基因的抗体递送

下一步

Nanoparticle-based Formulation to Drive Transformational Growth Across Inhaled Vaccines and Monoclonal Antibodies

Inhalation drug delivery involves administering drugs to the lungs through the mouth (pulmonary route) or nose (intranasal route), enabling them to bypass the blood-brain barrier. Small molecules have been the main focus for inhalation delivery, but recent R&D and increased interest in inhalable COVID-19 vaccines have led to a shift toward inhalable biologics for conditions where injection delivery is the norm.

This Frost & Sullivan study highlights important formulations for inhalable biologics and examines the factors that drive or limit market growth. The research examines the pipeline of monoclonal antibodies and vaccines in development and evaluates R&D trends, partnership and collaboration trends, funding and investment analysis, patent analysis, and the outlook for inhalable biologics. The study identifies significant growth opportunities for industry players in the field.

Questions this study answers:

• 1. What factors drive or limit the industry's growth?

• 2. What are the innovative methods for formulating inhalable biologics?

• 3. What does the pipeline analysis for inhalable vaccines and monoclonal antibodies look like?

• 4. What are the R&D trends and projected developments of the technologies?

• 5. What are the funding evaluations, patent evaluations, regulatory environments, and trends for partnerships and collaborations for inhalable biologics?

• 6. What are the growth opportunities for technology developers in the inhalable biologics space?

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Inhaled Therapeutics Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology

Growth Opportunity Analysis

• Scope of Analysis
• The Need for Inhalation Biologics Formulation
• Inhalation Drug Delivery-Introduction
• Segmentation-Formulations for Drug Inhalation
• Pros and Cons of Formulation and Drug Delivery Systems for Inhalation
• Examples of Novel Formulations and Drug Delivery System for Inhalable Biologics
• Promising Inhalation Therapy-Advantages of Inhalational Monoclonal Antibodies (mAbs) and Vaccines
• Growth Drivers
• Growth Restraints

Industry Assessment and Analysis

• Pipeline Analysis of Inhaled Vaccines and mAbs
• Vaccines and mAbs under Clinical Development
• Primary Technologies-AttenuBlock Platform Technology (Codon Deoptimization for Live Attenuated Vaccine Candidates)
• Primary Technologies-Nanoemulsion Platform (Intranasal Adjuvant Technology)

Innovation Ecosystem

• R&D Trends
• Collaboration and Partnership Trends
• Funding and Investment Analysis
• Patent Analysis
• Future Roadmap

Growth Opportunity Universe

• Growth Opportunity 1: Drug Repurposing Using Nanotechnology to Produce a Nebulizer Solution
• Growth Opportunity 2: Partnering with a CDMO that Offers End-to-end Services
• Growth Opportunity 3: Gene-based Antibody Delivery for Safe Inhaled Administration

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• Legal Disclaimer